C. Fernandez

发表

Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study.

A. Awada, D. Castellano, V. Moreno, 2022, European journal of cancer.

Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study

G. Shapiro, I. Braña, B. Pistilli, 2022, ESMO open.

Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study

G. Shapiro, I. Braña, A. Awada, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.

Michael Bittner, David Mallery, David M Loesch, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy

J. Baselga, J. Garber, N. Tung, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors

W. Pierceall, G. Shapiro, M. Borad, 2011, Clinical Cancer Research.

Cancer Therapy : Clinical Phase I Studies of CBP 501 , a G 2 Checkpoint Abrogator , as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors

W. Pierceall, G. Shapiro, M. Borad, 2011 .

Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL).

I. Vergote, I. Ray-Coquard, I. Benjamin, 2021, Gynecologic oncology.

Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer

I. Ray-Coquard, C. Galmarini, D. Berton‐Rigaud, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.

S. Peters, A. Santoro, K. Zaman, 2020, The Lancet. Oncology.

Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.

S. Peters, A. Santoro, K. Zaman, 2020, Lung cancer.

The gonyautoxin 2/3 epimers reduces anal tone when injected in the anal sphincter of healthy adults.

C. Jensen, N. Lagos, K. Lattes, 2004, Biological research.

Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial.

K. Zaman, L. Paz-Ares, A. Awada, 2019, Journal of Clinical Oncology.

Lurbinectedin (PM01183), an active compound in platinum-resistant/refractory ovarian cancer (PRROC) patients: Results of a two-stage, controlled phase II study.

I. Ray-Coquard, A. Nieto, C. Kahatt, 2014 .

Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study.

K. Zaman, J. Sehouli, A. Leary, 2023, Investigational new drugs.

CORAIL trial: Randomized phase III study of lurbinectedin (PM01183) versus pegylated liposomal doxorubicin (PLD) or topotecan (T) in patients with platinum-resistant ovarian cancer.

I. Vergote, I. Ray-Coquard, A. Nieto, 2016 .